Clovis Oncology (NASDAQ:CLVS) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Saturday.

A number of other analysts also recently issued reports on CLVS. ValuEngine downgraded Clovis Oncology from a “hold” rating to a “sell” rating in a report on Tuesday. Leerink Swann reduced their target price on Clovis Oncology to $107.00 and set an “outperform” rating for the company in a report on Friday, August 18th. J P Morgan Chase & Co reissued a “buy” rating on shares of Clovis Oncology in a report on Friday, August 18th. Evercore ISI started coverage on Clovis Oncology in a report on Wednesday, August 16th. They issued an “in-line” rating and a $73.00 target price for the company. Finally, Oppenheimer reissued a “hold” rating on shares of Clovis Oncology in a report on Tuesday, October 10th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $86.15.

Shares of Clovis Oncology (NASDAQ:CLVS) opened at $62.15 on Friday. The company has a quick ratio of 3.16, a current ratio of 3.19 and a debt-to-equity ratio of 0.94. Clovis Oncology has a fifty-two week low of $35.38 and a fifty-two week high of $99.45.

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.18) by ($0.06). The business had revenue of $16.81 million for the quarter, compared to analysts’ expectations of $21.12 million. Clovis Oncology had a negative return on equity of 122.06% and a negative net margin of 947.47%. During the same period last year, the firm earned ($1.70) earnings per share. equities research analysts anticipate that Clovis Oncology will post -7.63 earnings per share for the current fiscal year.

In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $84.54, for a total transaction of $253,620.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Thorlef Spickschen sold 4,500 shares of the business’s stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $60.00, for a total value of $270,000.00. Following the transaction, the director now owns 25,618 shares in the company, valued at approximately $1,537,080. The disclosure for this sale can be found here. Insiders have sold a total of 13,500 shares of company stock worth $923,220 in the last quarter. 12.50% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in shares of Clovis Oncology by 10.2% in the 2nd quarter. Vanguard Group Inc. now owns 3,618,843 shares of the biopharmaceutical company’s stock worth $338,831,000 after acquiring an additional 333,648 shares during the period. Orbimed Advisors LLC grew its holdings in shares of Clovis Oncology by 13.5% in the 3rd quarter. Orbimed Advisors LLC now owns 2,388,670 shares of the biopharmaceutical company’s stock worth $196,826,000 after acquiring an additional 284,300 shares during the period. State Street Corp grew its holdings in shares of Clovis Oncology by 4.3% in the 2nd quarter. State Street Corp now owns 1,943,480 shares of the biopharmaceutical company’s stock worth $181,966,000 after acquiring an additional 80,171 shares during the period. Franklin Resources Inc. grew its holdings in shares of Clovis Oncology by 70.3% in the 2nd quarter. Franklin Resources Inc. now owns 1,665,200 shares of the biopharmaceutical company’s stock worth $155,913,000 after acquiring an additional 687,300 shares during the period. Finally, Jennison Associates LLC grew its holdings in shares of Clovis Oncology by 222.5% in the 2nd quarter. Jennison Associates LLC now owns 1,185,177 shares of the biopharmaceutical company’s stock worth $110,968,000 after acquiring an additional 817,677 shares during the period.

COPYRIGHT VIOLATION NOTICE: “Clovis Oncology (CLVS) Lifted to “Sell” at BidaskClub” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/09/clovis-oncology-clvs-lifted-to-sell-at-bidaskclub.html.

About Clovis Oncology

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.